Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.
about
Cytomegalovirus-induced immunopathology and its clinical consequencesHigh incidence of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 infections in children with cancerCMV in Hematopoietic Stem Cell TransplantationVaccines: the Fourth CenturyImmunity to Infections after Haploidentical Hematopoietic Stem Cell TransplantationMesenchymal stromal cell therapy is associated with increased adenovirus-associated but not cytomegalovirus-associated mortality in children with severe acute graft-versus-host disease.Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenFrom patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138.Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation.Humoral and cellular CMV responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donorsBlood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associatedMurine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection.Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsγδ T cells confer protection against murine cytomegalovirus (MCMV).Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis.Cytomegalovirus-associated ulceration of gastric conduit after chemoradiotherapy following esophagectomy for cancerMonocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.Cytomegalovirus in hematopoietic stem cell transplant recipientsImmunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation PracticesProcedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytesDonor CD4 T Cell Diversity Determines Virus Reactivation in Patients After HLA-Matched Allogeneic Stem Cell TransplantationPharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.Immunobiology of human cytomegalovirus: from bench to bedside.How we treat cytomegalovirus in hematopoietic cell transplant recipients.Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.Novel strategies for adoptive therapy following HLA disparate transplantsComparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.CMV-specific immune reconstitution following allogeneic stem cell transplantation.Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8+ T Cell Responses According to Human Leukocyte Antigen Class I Allotypes and Intraindividual Dominance.Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients.Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation.
P2860
Q21195897-AB778A53-D618-4739-8324-F5538E77484DQ24800206-0F18F332-5EF3-4252-8843-A24223FA382CQ26740385-41CD995D-CCAC-45C0-B539-DEBC8CFE7D10Q27490454-0EA41D31-F377-4730-AFD2-371F4D5F1688Q28079606-8BB5FA99-6B75-49C4-8FD0-2A88766F7CB7Q30585387-D98C0A0C-FCEA-4F22-BF0D-2B954CB5EC4BQ33576882-9EF065BA-BA52-4C65-B326-7FA6CFCFBEE6Q33643203-C707D7BD-5F00-4B5B-BCBA-203C979E6820Q33645271-0C401FB9-823C-4BF2-B112-FF9EAF6215A9Q33766984-F6E53D1B-E2DC-4CE9-96DE-333B295BF9C8Q33853830-B329200F-9BF1-4C22-B256-54DF753AA801Q33878986-1C46473B-D110-45EA-B60D-910AD01289F3Q34121789-FC58E2CA-F8A1-4604-BC77-676744C41073Q34162822-28423A5B-56BA-4211-A891-56FD24856C97Q34626390-E8112A07-02A0-4F0D-B064-A6FF46A0AC9FQ34676355-9094F0CF-31B4-44C9-89EB-E22AFDCF92C2Q35553386-4C8465F9-9486-4BD9-AFA8-4B08043058C6Q35573003-99D9CAE6-B360-4A1D-94BF-0C918FCCF160Q35801652-3A439735-4F60-41BB-BAE2-EA937732D304Q35812694-DA5D6C75-16ED-4457-9CB5-7C23B87B08C1Q35847753-C6E76B8C-33A4-4D60-811A-15A1A6E7A0D0Q35848108-AAAE0A09-AB14-4D64-BA92-4E112C6A350AQ35922928-0B96C016-3DC1-4F6C-BF64-08CDBF9D4A54Q35958223-1791192A-4C55-45F5-B93E-4CD661A0AA5BQ35975542-8D69209F-42D8-4A3E-A3C3-E7104DDDF403Q36190463-48E9CE80-4463-4ED8-B446-5638D8BA7F94Q36302494-1588542A-0C4E-45C0-BC12-4ABAC386559EQ36709854-674B00A4-B7F6-4FFA-BECA-039AED1FB583Q37050965-FDF77050-60FA-4BCA-9EE7-148CAF0B74CFQ37237427-40026547-0838-43B9-A1D1-91308FE10326Q37262446-965716E2-F606-4BF1-AD65-25AF94F5F641Q37504394-0083261F-73B1-4AA4-AF3E-15F0C85CFFD4Q37618838-67AB397B-4F14-4B67-90F3-8BEF245F68F5Q38942459-D14E7691-C369-4DC2-8CB5-95D8BB106FD6Q40092234-13A2B428-94EB-4B40-85BE-027C3E7770E6Q41978755-73CCD1B6-14FC-48E4-9A05-21219A8E8F15Q42271011-F921A428-E7CE-4A92-9BB2-64FC803AF691Q47111092-5B09DE1D-EBD5-44AC-ACE0-D0034E6EC7A6Q47152509-7B3598A9-0094-475E-BF87-7D1BDC435B99Q52564628-20704685-462E-4BE6-844C-3F5F182345E5
P2860
Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Increased transplant-related m ...... ted stem cell transplantation.
@ast
Increased transplant-related m ...... ted stem cell transplantation.
@en
type
label
Increased transplant-related m ...... ted stem cell transplantation.
@ast
Increased transplant-related m ...... ted stem cell transplantation.
@en
prefLabel
Increased transplant-related m ...... ted stem cell transplantation.
@ast
Increased transplant-related m ...... ted stem cell transplantation.
@en
P2093
P1433
P1476
Increased transplant-related m ...... eted stem cell transplantation
@en
P2093
Cornelissen JJ
Gratama JW
Henzen-Logmans S
Kuenen-Boumeester V
Löwenberg B
van Der Holt R
van Esser JW
P304
P407
P577
2000-04-01T00:00:00Z